ロード中...

Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small cell lung cancer cells

Epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI) is the first choice of treatment for advanced non-small cell lung cancer (NSCLC) patients harbouring activating EGFR mutations. However, single agent usually has limited efficacy due to heterogeneous resistant mechanisms of canc...

詳細記述

保存先:
書誌詳細
出版年:Oncotarget
主要な著者: Wang, Miao, Yuang-Chi Chang, Alex
フォーマット: Artigo
言語:Inglês
出版事項: Impact Journals LLC 2018
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5893260/
https://ncbi.nlm.nih.gov/pubmed/29662665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24814
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!